Global Information
회사소개 | 문의 | 비교리스트

하이드록시클로로퀸 약 시장 : 성장, 동향, 예측(2020-2025년)

Hydroxychloroquine Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2022년 01월 상품코드 965024
페이지 정보 영문 배송안내 2-3일 (영업일 기준)
US $ 4,750 ₩ 6,176,000 PDF (Single User License)
US $ 5,250 ₩ 6,827,000 PDF (Team License: Up to 7 Users)
US $ 6,500 ₩ 8,452,000 PDF (Site License)
US $ 8,750 ₩ 11,378,000 PDF (Corporate License)

하이드록시클로로퀸 약 시장 : 성장, 동향, 예측(2020-2025년) Hydroxychloroquine Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
발행일 : 2022년 01월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 하이드록시클로로퀸 약 시장 규모는 예측 기간 중 약 16.8%의 CAGR로 확대할 것으로 예측됩니다. 하이드록시클로로퀸은 클로로퀸보다 안전한 유도체입니다. 하이드록시클로로퀸은 말라리아 치료 또는 예방에 적응되는 면역 억제 및 항기생충약이나, 이 약은 클로로퀸 내성 말라리아에는 효과가 없습니다. 하이드록시클로로퀸은 전신성 및 원판상 홍반성 낭창 등의 자가면역질환 및 기타 약제가 효과가 없거나 사용할 수 없는 류마티스 관절염(급성 및 중증)에도 추천됩니다. 광역 스펙트럼의 하이드록시클로로퀸 약은 다양한 바이러스의 치료에 사용할 수 있습니다. 중국의 과학기술부에 따르면 하이드록시클로로퀸은 초기 임상시험에서 코로나바이러스를 블록하기 위한 유망한 프로파일을 나타낸 약 중 하나입니다.

최근 하이드록시클로로퀸은 코로나바이러스(COVID19) 환자의 치료에 유효하기 때문에 주목받고 있습니다. 중국으로부터의 보고에서는 클로로퀸이 시험관내에서 SARS-CoV-2를 저해할 가능성이 있는 것을 실증했습니다. 이 약은 코로나바이러스 환자의 치료에 높은 유효성이 있는 것을 시사하고 있습니다. 하이드록시클로로퀸은 코로나바이러스의 유망한 잠재적 치료법이 될 것으로 기대되고 있습니다. 미국 식품의약국(FDA)은 코로나바이러스(COVID19)를 치료하기 위한 긴급 사용을 위해 하이드록시클로로퀸을 지정했습니다.

신규 하이드록시클로로퀸의 수요 증가와 제네릭 의약품의 침투는 시장을 크게 성장시킬 것으로 예측됩니다. 예를 들면 2020년 3월, Novartis International AG는 코로나바이러스 검사에서 양성인 사람들에게 하이드록시클로로퀸의 유효성을 평가하기 위한 관리된 임상시험을 하기 위해 미국 보건복지부(HHS)에 3000만 회분의 하이드록시클로로퀸 정제 출하를 개시했습니다. 또한 제품의 승인이 증가하면 정부 자금이 증가하므로 시장에 강하게 침투할 것으로 보이고 있습니다.

COVID-19에 관한 환자의 인식 향상과 세계 무대에서 새로운 제네릭 의약품의 유입에 의해 하이드록시클로로퀸 약의 채택이 가속할 것으로 예측됩니다. Johns Hopkins University에 따르면 2020년 4월 15일 시점에 미국에서만 약 609,516명이 COVID-19로 이환하고 있습니다. 질병 치료에 관한 인식의 향상, COVID-19의 치료에서 하이드록시클로로퀸의 유효성을 평가하기 위한 임상시험의 증가는 매출을 확대시킬 것으로 추정되고 있습니다. 그러나 저소득국에서의 낮은 헬스케어 접근성은 시장의 성장을 억제할 가능성이 있습니다.

하이드록시클로로퀸 약 시장에 대해 조사했으며, 시장의 개요와 용도별, 유통 채널별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.


제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 촉진요인
    • 코로나바이러스(COVID 19) 등의 질병 발생
    • 말라리아와 류마티스 관절염의 높은 유병률
    • 제품 발매와 승인의 증가
    • 다양한 치료 조건에서 하이드록시클로로퀸의 용도 확대
  • 시장 억제요인
    • 하이드록시클로로퀸의 세계 부족
    • 저소득국에서의 낮은 헬스케어 접근성
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 용도별
    • 코로나바이러스(COVID-19)
    • 말라리아
    • 홍반성 낭창
    • 류마티스 관절염
  • 유통 채널별
    • 온라인 약국
    • 원내 약국
    • 소매 약국
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Laurus Labs Limited,
    • Lupin
    • Mylan NV
    • Novartis International AG
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceuticals USA Inc.
    • Zydus Pharmaceuticals

제7장 시장 기회 및 향후 전망

KSA 20.11.12

The global hydroxychloroquine drugs market studied was anticipated to register a CAGR of nearly 16.8% during the forecast period. Hydroxychloroquine is a safer derivative of chloroquine. Hydroxychloroquine is an immunosuppressive and anti-parasite drug indicated for the treatment or prevention of malaria, although the drug is ineffective for chloroquine-resistant malaria. Hydroxychloroquine is also recommended for autoimmune diseases such as systemic and discoid lupus erythematosus, and rheumatoid arthritis (acute and severe) when other medications fail to work or cannot be used. Broad-spectrum hydroxychloroquine drugs can be used to treat a range of viruses. According to China's Ministry of Science and Technology, hydroxychloroquine is one of the drugs which demonstrated encouraging profile for blocking coronavirus in early clinical trials.

Recently, hydroxychloroquine has attracted attention due to its effectiveness in treating patients with coronavirus disease (COVID 19). Reports from China demonstrated chloroquine could possibly inhibit SARS-CoV-2 in vitro. The drug showed high efficacy in treating the patients with coronavirus disease (COVID 19). Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19).

Increasing demand for novel hydroxychloroquine and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, in March 2020, Novartis International AG started the shipping of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for controlled clinical studies to evaluate the effectiveness of hydroxychloroquine in people who have tested positive for coronavirus disease (COVID 19). In addition, increasing product approval is poised to have strong market penetration due to the presence of increased government funding.

Growing patient awareness regarding COVID-19 and the influx of new generics in the global arena are projected to accelerate the adoption of hydroxychloroquine drugs. As per the Johns Hopkins University, as of 15th April 2020, approximately 609,516 people suffered from COVID-19 in the US alone. Increasing awareness regarding disease remittance therapies, rising clinical trials to evaluate the effectiveness of hydroxychloroquine in the treatment of COVID-19 are estimated to promote revenue growth. However, poor healthcare accessibility in low-income countries may restrain the growth of the market.

Key Market Trends

Rheumatoid Arthritis Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

  • Rheumatoid arthritis is expected to dominate the global hydroxychloroquine drugs market through the forecast period. This can be attributed to the rising prevalence of rheumatoid arthritis, which causes different symptoms, such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and the risk of joint replacement.
  • According to the World Health Organization, more than 23 million people live with rheumatoid arthritis. Thus, the rheumatoid arthritis segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and low price of generic drugs for the target disease are supplementing the growth of the segment.
  • Moreover, COVID-19 is estimated to be the fastest-growing segment over the forecast period. Exponentially increasing cases worldwide is the major factor expected to drive the vertical over the forecast period. The World Health Organization declared coronavirus disease (COVID 19) as a pandemic on March 11, 2020. As per the Johns Hopkins University, till the date April 15, COVID-19 is responsible for more than 126,859 deaths worldwide. Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19). All the aforementioned factors expected to bode a well for this vertical.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of RA and COVID-19, and high public and private healthcare spending are stimulating the growth of the region. Moreover, the World Health Organization estimates that by the end of 2040, 54.4 million adults in the country may suffer from rheumatoid arthritis. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

Asia-Pacific is likely to post the fastest market throughout the forecast horizon. Lack of disease awareness in some underdeveloped regions is leading to an expanding base of patients in the region. This, coupled with increasing healthcare spending, presence of key manufacturers, such as Zydus Cadila, Novartis, and Sun Pharmaceuticals, and growing product approvals, is expected to propel the market in APAC. Increasing demand for target drug for disease reversal is poised to augment the regional markets during the forecast period.

Competitive Landscape

Manufacturers offering generic versions dominate the global hydroxychloroquine drugs market. Companies are focusing on building generic chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are DR. REDDY'S LABORATORIES LTD, Laurus Labs Limited, Lupin, Mylan NV, Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc., and Zydus Pharmaceuticals.

The introduction of generic versions and the strong clinical pipeline is anticipated to increase competition in the market. For instance, in April 2020, Zydus Cadila and Ipca Labs have backward integrated HCQ making capability with the aim to increase production capacity by 5-6 times to 70 MT per month thereby, expanding the range of treatment options for the millions of patients living with target diseases.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Disease Outbreaks Such As Coronavirus Disease (COVID 19)
    • 4.2.2 High prevalence of Malaria and Rheumatoid Arthritis
    • 4.2.3 Increasing Product Launches and Approvals
    • 4.2.4 Expanding Application of Hydroxychloroquine in Various Therapeutic Conditions
  • 4.3 Market Restraints
    • 4.3.1 Global Shortage of Hydroxychloroquine
    • 4.3.2 Poor Healthcare Accessibility in Low Income Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Application
    • 5.1.1 Coronavirus Disease (COVID-19)
    • 5.1.2 Malaria
    • 5.1.3 Lupus Erythematosus
    • 5.1.4 Rheumatoid Arthritis
  • 5.2 By distribution Channel
    • 5.2.1 Online Pharmacy
    • 5.2.2 Hospital Pharmacy
    • 5.2.3 Retail Pharmacy
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.2 Laurus Labs Limited,
    • 6.1.3 Lupin
    • 6.1.4 Mylan NV
    • 6.1.5 Novartis International AG
    • 6.1.6 Sanofi SA
    • 6.1.7 Sun Pharmaceutical Industries Ltd
    • 6.1.8 Teva Pharmaceuticals USA Inc.
    • 6.1.9 Zydus Pharmaceuticals


Back to Top
전화 문의